Quoin Prescription drugs Pronounces Opening of First Medical

Quoin Prescription drugs Pronounces Opening of First Medical

ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) — Quoin Prescription drugs Ltd. (NASDAQ: QNRX) (the “Firm” or “Quoin”), a specialty pharmaceutical firm centered on uncommon and orphan illnesses, proclaims that the primary medical web site has now been totally opened for its medical research to guage QRX003 for the remedy of the uncommon genetic illness, Netherton Syndrome. The opening of extra websites is in course of and affected person recruitment is anticipated to start shortly.

This randomized, double blinded, vehicle-controlled research is being carried out underneath a U.S. Investigational New Drug (IND) Software and can assess two totally different doses of QRX003 topical lotion versus a car lotion in Netherton sufferers. The check supplies shall be utilized as soon as every day over a twelve-week interval, to pre-designated areas of the affected person’s physique. Based mostly on discussions with the U.S. Meals and Drug Administration (FDA), a variety of totally different medical endpoints shall be assessed within the research.

The lively ingredient in QRX003 is a broad spectrum serine protease inhibitor, whose mechanism of motion is meant to down-regulate the hyperactivity of pores and skin kallikreins resulting in a extra normalized charge of pores and skin shedding. If confirmed to be protected and efficient, long run every day software of QRX003 might result in the event of a extra usually functioning pores and skin barrier and a major enchancment within the high quality of lifetime of Netherton sufferers.

Quoin CEO, Dr. Michael Myers, mentioned, “We’re more than happy to announce one other vital milestone within the growth of QRX003 for this very underserved affected person inhabitants. The opening of this primary medical web site, with full Institutional Evaluation Board approval, is testimony to the nice work of our CRO, Therapeutics Inc. With the opening of extra websites properly underway, we’re poised to provoke affected person recruitment shortly.

“That is additionally an vital step ahead for our companions with whom we now have established provide and distribution agreements for QRX003 in 60 international locations, because it doubtlessly advances the trail to approval of their territories. Moreover, many of those areas have early-access packages that the info from this research might doubtlessly allow QRX003 to take part in, and be made accessible on a named affected person foundation previous to formal regulatory approval.”

Together with the corporate’s technique of self-commercializing its portfolio of merchandise within the U.S. and Europe, Quoin has established a world community of promoting partnerships for QRX003 that may assist assist its mission of guaranteeing that each affected person, in all places, can entry Quoin’s merchandise, as soon as permitted.

About Quoin Prescription drugs Ltd.
Quoin Prescription drugs Ltd. is a medical stage specialty pharmaceutical firm centered on growing and commercializing therapeutic merchandise that deal with uncommon and orphan illnesses. We’re dedicated to addressing unmet medical wants for sufferers, their households, communities and care groups. Quoin’s modern pipeline includes 4 merchandise in growth that collectively have the potential to focus on a broad variety of uncommon and orphan indications, together with Netherton Syndrome, Peeling Pores and skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For extra info, go to: www.quoinpharma.com or LinkedIn for updates.

Cautionary Word Concerning Ahead Trying Statements
The Firm cautions that statements on this press launch that aren’t an outline of historic information are forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements could also be recognized by way of phrases referencing future occasions or circumstances reminiscent of “count on,” “intend,” “plan,” “anticipate,” “imagine,” and “will,” amongst others. As a result of such statements are topic to dangers and uncertainties, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. These forward-looking statements are primarily based upon the Firm’s present expectations and contain assumptions which will by no means materialize or could show to be incorrect. Precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of varied dangers and uncertainties. Extra detailed details about the dangers and uncertainties affecting the Firm is contained underneath the heading “Danger Elements” included within the Firm’s Annual Report on Kind 20-F filed with the SEC on April 14, 2022, and in different filings the Firm has made and will make with the SEC sooner or later. One mustn’t place undue reliance on these forward-looking statements, which communicate solely as of the date on which they had been made. As a result of such statements are topic to dangers and uncertainties, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. The Firm undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they had been made, besides as could also be required by regulation.

For additional info, contact:

Quoin Prescription drugs Ltd.
Michael Myers, Ph.D., CEO

Investor Relations
PCG Advisory
Stephanie Prince
(646) 863-6341